|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
122,563,000 |
Market
Cap: |
8.01(B) |
Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,262 |
52
Week Range: |
$26.88 - $108.06 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
138,376 |
249,012 |
432,485 |
896,841 |
Total Sell Value |
$10,230,342 |
$16,723,328 |
$23,122,951 |
$44,047,420 |
Total People Sold |
3 |
4 |
5 |
11 |
Total Sell Transactions |
7 |
18 |
40 |
83 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Henderson John T |
Director |
|
2024-04-25 |
4 |
AS |
$64.54 |
$681,671 |
D/D |
(10,562) |
32,070 |
|
1% |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-04-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
150 |
138,417 |
|
- |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-04-09 |
4 |
S |
$74.31 |
$2,422,918 |
D/D |
(32,605) |
138,567 |
|
14% |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-04-09 |
4 |
OE |
$6.67 |
$190,795 |
D/D |
28,605 |
171,172 |
|
- |
|
Callos Andrew |
EVP, Chief Commercial Officer |
|
2024-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,941 |
63,887 |
|
- |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
21,333 |
142,567 |
|
- |
|
Wong Robert |
VP, Chief Accounting Officer |
|
2024-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,079 |
29,664 |
|
- |
|
Blum Robert I |
President & CEO |
|
2024-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
61,490 |
461,221 |
|
- |
|
Callos Andrew |
EVP, Chief Commercial Officer |
|
2024-03-06 |
4 |
D |
$66.88 |
$341,289 |
D/D |
(5,103) |
46,946 |
|
- |
|
Wong Robert |
VP, Chief Accounting Officer |
|
2024-03-06 |
4 |
D |
$66.88 |
$57,316 |
D/D |
(857) |
25,585 |
|
- |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-03-06 |
4 |
D |
$66.88 |
$542,330 |
D/D |
(8,109) |
121,234 |
|
- |
|
Blum Robert I |
President & CEO |
|
2024-03-06 |
4 |
D |
$66.88 |
$1,118,568 |
D/D |
(16,725) |
399,731 |
|
- |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-03-05 |
4 |
AS |
$67.53 |
$2,202,606 |
D/D |
(32,604) |
138,973 |
|
-2% |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-03-05 |
4 |
OE |
$6.67 |
$190,789 |
D/D |
28,604 |
167,577 |
|
- |
|
Callos Andrew |
EVP, Chief Commercial Officer |
|
2024-03-04 |
4 |
D |
$67.68 |
$149,031 |
D/D |
(2,202) |
52,049 |
|
- |
|
Wong Robert |
VP, Chief Accounting Officer |
|
2024-03-04 |
4 |
D |
$67.68 |
$120,673 |
D/D |
(1,783) |
26,442 |
|
- |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-03-04 |
4 |
D |
$67.68 |
$651,758 |
D/D |
(9,630) |
133,343 |
|
- |
|
Blum Robert I |
President & CEO |
|
2024-03-04 |
4 |
D |
$67.68 |
$1,715,079 |
D/D |
(25,341) |
416,456 |
|
- |
|
Henderson John T |
Director |
|
2024-02-14 |
4 |
AS |
$76.48 |
$382,400 |
D/D |
(5,000) |
42,632 |
|
-15% |
|
Henderson John T |
Director |
|
2024-02-14 |
4 |
OE |
$4.44 |
$22,200 |
D/D |
5,000 |
47,632 |
|
- |
|
Blum Robert I |
President & CEO |
|
2024-02-13 |
4 |
AS |
$76.85 |
$960,625 |
D/D |
(12,500) |
441,797 |
|
-15% |
|
Blum Robert I |
President & CEO |
|
2024-02-13 |
4 |
OE |
$6.67 |
$83,375 |
D/D |
12,500 |
454,297 |
|
- |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-02-06 |
4 |
AS |
$79.28 |
$2,585,497 |
D/D |
(32,605) |
142,973 |
|
-18% |
|
Malik Fady Ibraham |
EVP Research & Development |
|
2024-02-06 |
4 |
OE |
$6.67 |
$190,795 |
D/D |
28,605 |
175,578 |
|
- |
|
Blum Robert I |
President & CEO |
|
2024-01-31 |
4 |
AS |
$79.57 |
$994,625 |
D/D |
(12,500) |
441,797 |
|
-16% |
|
1093 Records found
|
|
Page 1 of 44 |
|
|